TY - JOUR
T1 - Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper
AU - Busca, A.
AU - Cattaneo, C.
AU - De, Carolis E.
AU - Nadali, G.
AU - Offidani, M.
AU - Picardi, M.
AU - Candoni, A.
AU - Ceresoli, E.
AU - Criscuolo, M.
AU - Delia, M.
AU - Della, Pepa R.
AU - Del, Principe I.
AU - Fanci, R. R.
AU - Farina, F.
AU - Fracchiolla, N.
AU - Giordano, C.
AU - Malagola, M.
AU - Marchesi, F.
AU - Piedimonte, M.
AU - Prezioso, L.
AU - Quinto, A. M.
AU - Spolzino, A.
AU - Tisi, M. C.
AU - Trastulli, F.
AU - Trecarichi, E. M.
AU - Zappasodi, P.
AU - Tumbarello, M.
AU - Pagano, Livio
PY - 2021
Y1 - 2021
N2 - The therapeutic armamentarium for the treatment of patients with lymphoproliferative diseases has grown considerably over the most recent years, including a large use of new immunotherapeutic agents. As a consequence, the epidemiology of infectious complications in this group of patients is poorly documented, and even more importantly, the potential benefit of antimicrobial prophylaxis remains a matter of debate when considering the harmful effect from the emergence of multidrug resistant pathogens. The present position paper is addressed to all hematologists treating patients affected by lymphoproliferative malignancies with the aim to provide clinicians with a useful tool for the prevention of bacterial, fungal and viral infections.
AB - The therapeutic armamentarium for the treatment of patients with lymphoproliferative diseases has grown considerably over the most recent years, including a large use of new immunotherapeutic agents. As a consequence, the epidemiology of infectious complications in this group of patients is poorly documented, and even more importantly, the potential benefit of antimicrobial prophylaxis remains a matter of debate when considering the harmful effect from the emergence of multidrug resistant pathogens. The present position paper is addressed to all hematologists treating patients affected by lymphoproliferative malignancies with the aim to provide clinicians with a useful tool for the prevention of bacterial, fungal and viral infections.
KW - Anti-Bacterial Agents
KW - Anti-Infective Agents
KW - Antimicrobial prophylaxis
KW - Antimicrobial stewardship.
KW - Bacterial
KW - Fungal and viral infections
KW - Humans
KW - Lymphoproliferative Disorders
KW - Lymphoproliferative disorders
KW - Anti-Bacterial Agents
KW - Anti-Infective Agents
KW - Antimicrobial prophylaxis
KW - Antimicrobial stewardship.
KW - Bacterial
KW - Fungal and viral infections
KW - Humans
KW - Lymphoproliferative Disorders
KW - Lymphoproliferative disorders
UR - https://publicatt.unicatt.it/handle/10807/176222
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85099252160&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85099252160&origin=inward
U2 - 10.1016/j.critrevonc.2020.103203
DO - 10.1016/j.critrevonc.2020.103203
M3 - Article
SN - 1040-8428
VL - 158
SP - 103203
EP - 103213
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
IS - 158
ER -